[Oral actovegin therapy in cerebrovascular insufficiency. Studies on the therapeutic value of actovegin forte dragees in elderly patients with advanced cerebrovascular insufficiency].
The therapeutic effect of Actovegin forte drag. was investigated in a combined uncontrolled-controlled study on a total of 70 senile patients with mainly considerably advanced cerebral sclerosis (32 patients post-apoplexy) and concomitant diseases (46 patients with heart diseases, 41 patients with hypertonia, 28 patients with diabetes mellitus and others). Evaluation was made according to specific criteria. During six weeks of treatment with Actovegin a statistically significant and clinically relevant improvement of the intellectual faculties, the general condition and the complaints characterized by symptoms of deficiency of memory, exhaustiveness, disorder of sleep and weakness was noted. Even higher doses of the preparation were tolerated well. The effect of Actovegin forte drag. was dose-dependent--the best results were obtained with two dragées three times daily--and was clearly delimited from the effect of a parallel cardiac or circulatory therapy or of any other basic therapy. These results reveal that the therapy with orally administered Actovegin appears to be an appropriate supplement to the parenteral therapy with Actovegin which has so far only been possible. It is particularly suitable for ambulatory and prolonged treatment of senile patients with cerebrovascular insufficiency.
D000368:Aged; D002561:Cerebrovascular Disorders / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D004361:Drug Tolerance; D005260:Female; D006418:Heme / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007360:Intelligence; D008297:Male; D008568:Memory
D006418:Heme
Orale Actovegin-Therapie bei zerebrovaskulärer Insuffizienz. Untersuchung über die therapeutische Wirksamkeit von Actovegin forte Dragées bei Alterspatienten mit fortgeschrittenen zerebrovaskulären Insuffizienzerscheinungen.